Abstracts tagged "SLE and toll-like receptors"

Abstract Number: 43 • 2017 ACR/ARHP Annual Meeting
Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE
Daniele Mauro¹, Victoria Tsang², Isabelle A. Clayton-Lucey³, Sara Pagani², Farah Alam², Elena Pontarini², Alessandra Nerviani², Angela Pakozdi⁴, Andrea Cove-Smith⁴, Ravindra Rajakariar⁴, Debasish Pyne⁴, Timothy J Vyse⁵, Costantino Pitzalis² and Myles J. Lewis^4,6, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom, ⁴Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, ⁵Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, United Kingdom, ⁶Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: A single risk haplotype spanning UBE2L3 is strongly associated with SLE and multiple autoimmune diseases. The E2 ubiquitin-conjugating enzyme UBE2L3 regulates TNFα and CD40…
Abstract Number: 1060 • 2017 ACR/ARHP Annual Meeting
Assessing Interferon Regulatory Factor 5 (IRF5) Function in Human Primary Immune Cells with Cell-Penetrating Peptides
Jaspreet Banga¹, Dinesh Srinivasan², Chia Chi Sun³, Francesca Milletti⁴, Kuo-Sen Huang⁵, Shannon Hamilton⁶, Ann F. Hoffman⁵, Yajuan G. Qin², Sandip Panicker², Gang Lu², Dan Li⁷, Hong Qian⁵, David R. Bolin⁵, Lena Liang⁵, Charles Wartchow⁵, Nader Fotouhi⁵, Julie A. DeMartino³, Seng-Lai Tan², Gang Chen³ and Betsy J. Barnes⁷, ¹The Feinstein Institute for Medical Research, Manhasset, NY, ²Inflammation Discovery, Hoffmann-La Roche, Inc., Nutley, NJ, ³TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA, ⁴Roche Innovation Center New York, New York, NY, ⁵Hoffmann-La Roche, Inc., Nutley, NJ, ⁶Hoffmann-La Roche, Inc., Nutley, NJ, Afghanistan, ⁷Center for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Interferon regulatory factor 5 (IRF5) is a key mediator of pathogen-induced immune responses that acts downstream of Toll-like receptors (TLRs), NOD-like receptors (NLRs) and…
Abstract Number: 2869 • 2014 ACR/ARHP Annual Meeting
TLR7 Influences Autoreactive B Cell Selection in the Germinal Center
Weiqing Huang¹, Megan Woods¹, Alexis Boneparth², Ramalingam Bethunaickan¹, Ranjit Sahu¹ and Anne Davidson¹, ¹Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Pediatric Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: TLR7 is required for the generation of anti-RNA antibodies and excess TLR7 confers a SLE-like phenotype in mice. Recent studies have shown that TLR7…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].